POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.

Start Date11 Jan 2023

Sponsor / Collaborator

McMaster University

[+1]

NCT04855526 / Unknown statusEarly Phase 1IIT

Effects of Marijuana on Memory-Related Neurochemistry and Neural Response

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Start Date01 Apr 2022

Sponsor / Collaborator

Hartford Hospital

[+1]

NCT03550352 / TerminatedPhase 2IIT

Cannabinoids in People Living With HIV on Effective Antiretroviral Therapy: A Pilot Study to Assess Safety, Tolerability and Effect on Immune Activation

The purpose of this pilot study is to assess feasibility and to examine whether oral cannabinoids (capsules containing either Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) combined or CBD alone) are safe and well-tolerated in people living with HIV. Other aims are to determine whether oral cannabinoids may reduce HIV-associated inflammation. An exploratory objective is to determine whether oral cannabinoids may influence HIV persistence as well as the gastrointestinal microbiome.

Start Date20 Aug 2021

Sponsor / Collaborator

McGill University Health Center

[+3]

100 Clinical Results associated with Cannabidiol/Tetrahydrocannabivarin

100 Translational Medicine associated with Cannabidiol/Tetrahydrocannabivarin

100 Patents (Medical) associated with Cannabidiol/Tetrahydrocannabivarin

Literatures (Medical) associated with Cannabidiol/Tetrahydrocannabivarin

01 Nov 2022·Psychopharmacology

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis

Article

Author: Kevin, R C ; Theunissen, E L ; Schepers, J ; McGregor, I S ; Vinckenbosch, F ; Hutten, Nadia R P W ; Ramaekers, J G ; Kuypers, K P C ; Arkell, T R

Abstract RationaleDelta-9-tetrahydrocannabinol (THC), an active component of cannabis, can cause anxiety in some users during intoxication. Cannabidiol (CBD), another constituent of cannabis, has anxiolytic properties suggesting that cannabis products containing CBD in addition to THC may produce less anxiety than THC-only products. Findings to date around this issue have been inconclusive and could conceivably depend on moderating factors such as baseline anxiety levels in users.ObjectiveThe present study examined whether anxiety following single doses of vaporised THC, CBD and THC/CBD might be explained by state and trait anxiety levels at baseline.MethodsA placebo-controlled, randomised, within-subjects study including 26 healthy recreational cannabis users tested the effects of vaporised THC-dominant cannabis (13.75 mg THC), CBD-dominant cannabis (13.75 mg CBD), THC/CBD-equivalent cannabis (13.75 mg THC/13.75 mg CBD) and placebo cannabis on anxiety. Self-rated trait anxiety was assessed with the State-Trait Anxiety Inventory (STAI). State levels of anxiety were objectively assessed with a computer-based emotional Stroop task (EST) and subjectively rated with the STAI-state questionnaire and a visual analogue scale.ResultsBoth THC and THC/CBD significantly increased self-rated state anxiety compared to placebo. State anxiety after THC/CBD was significantly lower than after THC alone. THC-induced anxiety was independent of anxiety at baseline. When baseline anxiety was low, CBD completely counteracted THC-induced anxiety; however, when baseline anxiety was high, CBD did not counteract THC-induced anxiety. There were no effects of any treatment condition on the EST.ConclusionOverall, the study demonstrated that the THC/CBD-equivalent cannabis induces less state anxiety than THC-dominant cannabis.

01 Apr 2021·European Journal of Applied PhysiologyQ3 · MEDICINE

Time-series analysis of heart rate and blood pressure in response to changes in work rate before and after 60 days of 6° head down tilt bed rest

Q3 · MEDICINE

Article

Author: Drescher, U ; Thieschäfer, L ; Koschate, Jessica ; Zieschang, T ; Hoffmann, U

AbstractPurposeCardiovascular regulation during exercise, described using time series analysis, is expected to be attenuated after bed rest (BR) and this effect will be dampened by a reactive jumps countermeasure.MethodsTwenty subjects (29 ± 6 years, 23.6 ± 1.7 kg m−2) were tested on a cycle ergometer 9 days (BDC-9) before the beginning of BR as well as 2 (R + 2) and 13 days (R + 13) after the end of BR, applying moderate pseudo-random binary (PRBS) work rate changes. Heart rate (HR) and mean arterial blood pressure (mBP) were measured beat-to-beat and interpolated to 1 s intervals. HR and mBP were cross-correlated [CCF(HR-mBP)] during the PRBS. Eleven subjects participated in a reactive jump countermeasure (JUMP) during the BR period, the other part of the group served as control group (CTRL).ResultsIn the CTRL group, significantly lower CCF(HR-mBP) values during BDC-9 were observed compared to R + 2 during the lags 20–25 s and significantly higher values during the lags − 39 s to − 35 s. In the JUMP group, significantly lower CCFs were only observed at R + 2 compared with BDC-9 during the lags 23 s and 24 s, whereas the CCFs for BDC-9 were significantly higher at several lags compared with R + 13.ConclusionAttenuations in the regulation of the cardiovascular system during cycling exercise after BR were found in the CTRL group of the RSL study. Cardiovascular regulation in the JUMP group was improved compared to values before the beginning of BR, suggesting the effectiveness of the reactive jumps countermeasure to mitigate the deleterious effects of prolonged BR.

News (Medical) associated with Cannabidiol/Tetrahydrocannabivarin

06 Mar 2023

·www.businesswire.com

CannaAid is the First Brand to Market With H4-CBD Within USA and Internationally

MOORESVILLE, N.C.--( BUSINESS WIRE )--CannaAid is pleased to announce that it is the first brand to produce and sell H4-CBD products on the market. This up-and-coming cannabinoid has generated a lot of interest in recent years, but only a few brands have been able to successfully launch it. CannaAid is excited to introduce its new line of H4-CBD cannabinoid products. About CannaAid CannaAid is one of the biggest cannabinoid-based producers in the United States, having been established in 2016. This USA-based business offers a wide range of premium cannabis products that contain both rare and common cannabinoids. CannaAid founder Lee VanTine takes pride in his company's ability to offer reasonably priced goods without compromising on quality. All of CannaAid’s products undergo extensive testing, with up-to-date COAs always available for consumers to view. As the cannabis & hemp industry continues to expand, so does CannaAid. Today, you can purchase top-shelf products containing popular budding cannabinoids such as HHC, delta-8, and H4-CBD. What is H4-CBD? Recently, the cannabis industry has introduced the concept of hydrogenation. Hydrogenation occurs when chemists add hydrogen atoms to cannabinoid molecules. This process causes a chemical reaction that changes the active cannabinoid into a different one, usually a stronger one. In the past few years, cannabis scientists have learned the advantages of hydrogenating THC molecules, a process that has traditionally been used in organic chemistry to create or purify specific ingredients or materials. HHC is the first major example of hydrogenation entering the cannabis industry. Now, chemists are finding ways to add hydrogen atoms to CBD molecules instead. By doing this, they create an enhanced version of CBD, which can be helpful for those seeking more intense relief. Because the H4-CBD cannabinoid comes from hemp-derived CBD, it is currently legal under the 2018 Farm Bill. However, very few retailers have branched out into the market, leaving CannaAid as one of the only producers out there with high-quality H4-CBD products to try. We are pleased to inform you that as CannaAid expands its presence in the United Kingdom (UK), they have confirmed that their H4-CBD product(s) meet all legal requirements in the UK. Under The Psychoactive Substances Act 2016 and the Misuse of Drugs Act 1971, the sale or use of psychoactive products is not allowed in the UK. CannaAid remains committed to providing customers with safe and legal products that meet the highest standards of quality and compliance in the United Kingdom (UK). Why H4-CBD? H4-CBD is very new to the market, but it appears to have good potential for various applications. CBD is a beneficial cannabinoid for those seeking relief, but its effects may not be powerful enough for all consumers, especially those with more chronic complications. Thus, H4-CBD may prove to be a better option. The H4-CBD cannabinoid is going to be much stronger than your typical CBD cannabinoid. In fact, many people report feeling the effects of extreme relaxation and a sense happiness from it, on top of the prominent therapeutic assistance. For those who have found that CBD is helpful but may not provide the full range of support that they’re looking for, H4-CBD is looking like the next step forward. Of course, it’s important to remember that this type of cannabinoid is still new and much more potent than consumers may be used to from CBD. Studies suggest that H4-CBD interacts with CB1 receptors 100 times more potently than CBD. However, it’s important to note that typical CBD doesn’t interact with CB1 receptors at all, so even H4-CBD’s 100-times interaction with the receptors won’t be overwhelming. Instead, people report the experience that of product that doesn’t compare to CBD plus all the benefits at a fraction of the amount needed to be consumed. This product will change CBD forever. H4-CBD Gummies & Disposable Vapes Right now, CannaAid is offering H4-CBD gummies to provide an enjoyable, easily dosed experience. Consumers will simply start with one gummy and wait about an hour for the effects to kick in. These H4-CBD gummies come in a strawberry watermelon flavor and contain a hefty 60 mg of H4-CBD in every gummy. You don’t want to miss out on these delicious gummies! In addition to these amazing new gummies, CannaAid is releasing a new lineup of H4-CBD Vapes. These vapes are packed with the same top-shelf H4-CBD as the gummies and are designed to provide users with a quick and convenient way to consume H4-CBD, and they come in a variety of strains to please every customer. With these new products, CannaAid is further expanding their line of H4-CBD products and demonstrating their commitment to providing customers with high-quality and innovative solutions for their wellness needs. You can also learn more about the CannaAid shop as a whole and explore its large inventory of cannabinoid products here: https://www.cannaaidshop.com/

25 Oct 2022

·www.biospace.com

BioHarvest Introduces its 1st Cannabis Breakthrough Composition with Major Medical and Commercial Implications

BioHarvest demonstrates unprecedented Cannabinoids tuning and elicitation capabilities (12X increase versus original plant) using its proprietary Bio-Plant CELLicitation™ platform technology Contains high amounts of minor Cannabinoids such as THCV (2.5%) and CBDV (4.4%) providing unique medical and commercial benefits The Company plans to reveal additional information related to its high THC Cannabis product line by year end Vancouver, British Columbia and Rehovot, Israel--(News - October 25, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") reveals today the detailed analysis (tabled below) of the unique composition of one of its Bio CELLicitation™ based Cannabis products that were grown from a CBD Hemp plant. The analysis is derived from using industry standard HPLC measurements conducted by an independent third-party analytical laboratory which is ISO17025 cGMP accredited and is certified by the Israeli Ministry of Health. To view an enhanced version of this graphic, please visit: In addition to the Cannabinoids described in the table above, the β-caryophyllene, Beta-panasinsene and Selina terpenes were present in the composition. Dr. Christopher D'Adamo, Director, Center for Integrated Medicine at the University of Maryland, School of Medicine said "The medical establishment has been eyeing the potential of full spectrum Cannabis to address many chronic health indications in need of better treatment options. These achievements by BioHarvest in naturally eliciting important minor Cannabinoids to significant biologically active levels, combined with high levels of major Cannabinoids, all produced with high level of consistency represent a major breakthrough towards the development of efficient Cannabis-based botanical drugs". Unique scientific, medicinal, and commercial features of this composition: • Ground-breaking Science - Increasing the total Cannabinoids from 3% in the original plant flower to 36% and increasing THC from 0.09% to 7.5% in the final product (83X) demonstrate the power of BHSC's Bio-Plant CELLicitation™ technology to control the Cannabinoids levels and ratios in a full spectrum composition. In addition, naturally eliciting rare minor cannabinoids such as CBDV (88X) and THCV (249X) to significant biological active levels in the same composition with high level of major Cannabinoids is unprecedented. • Medical Impact - Unique composition of significant amounts of major and minor Cannabinoids, in a full spectrum form, paves the road for multiple Cannabis-based therapeutic solutions targeting key chronic indications such as pain management, anxiety, sleep disorder and ADHD. • Commercial Implications - The ability to start from a CBD Hemp plant and control the THC levels in the final composition would allow BioHarvest to sell unique Hemp-based non-synthetic therapeutic products (including distillates) on a federally legal base in the US. The sales & marketing of such products will take advantage of the already established "Direct to Consumer" commercial platform successfully employed by BioHarvest for its VINIA® product. BioHarvest can also target a wider range of health and wellness applications with unique products that combine its Polyphenols-based (VINIA®, olives and pomegranate) compounds with the Hemp-based compositions. "This rich Cannabinoids composition is unprecedented, and the wealth of features described above opens the door for many lucrative commercial and medical applications", said Ilan Sobel, CEO, and added "the ability to produce unique Cannabis and Hemp based compositions gives us tremendous flexibility to decide which markets to pursue, what would be the optimal products offerings and partnerships. In addition, the high level of Cannabinoids, combined with our unique cost advantage opens the door for the production of distillates and isolates of specific cannabinoids resulting in multiple levers to optimize revenue and profitability from this vertical". Dr. Brian Cornblatt, CMO, who leads BioHarvest Sciences' product supportive clinical trial efforts shared "The ability for us to create novel compositions with vast intellectual property opportunities is exciting. The clinical trial potential using these compositions is endless and we are going to focus our efforts on bringing to the world safe, effective, consistent, and easily accessible solutions for, in time, many of the major health challenges that we now face". Q3 Shareholder Update October 25, 11am PST | 2PM EST This composition breakthrough will be discussed in detail at today's live Shareholder Update, and all shareholder partners, investors, media, and members of the scientific community are invited to register here: . The presentation will be approximately 45 minutes, followed by a live question and answer session. All registrants will receive a recording of the session, and any questions regarding the Company or the Q3 2022 Shareholder Update can be sent to info@bioharvest.com. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: dave@bioharvest.com Twitter: Facebook: LinkedIn: YouTube: Forward-Looking Statements Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. There is no assurance of commercial availability of our Cannabis product in 2022 or that the Company achieves the conversion of the two tons VINIA® facility to Cannabis production in 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured. There is no assurance that the company will develop medical solutions targeting key indicators such as ADHD, pain management and anxiety. Marketing products with such claims would require FDA approval in the US and similar approvals in other jurisdictions which would require a lengthy and expensive approval process including clinical trials the outcome of which would be uncertain and cannot be assured. Although the Farm Act has removed prohibitions on the sale of CBD from hemp products there is no assurance the company will be able to successfully market such products nationwide which would require significant marketing expenditures and customer acceptance that is uncertain and cannot be assured All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit

100 Deals associated with Cannabidiol/Tetrahydrocannabivarin

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	-	University of Buckingham	-
Diabetes Mellitus, Type 2	Phase 2	GB	GW Pharmaceuticals Ltd.	-
Dyslipidemias	Phase 2	-	University of Buckingham	-
Dyslipidemias	Phase 2	GB	GW Pharmaceuticals Ltd.	-
Metabolic Syndrome	Phase 2	-	University of Buckingham	-
Metabolic Syndrome	Phase 2	GB	GW Pharmaceuticals Ltd.	-
Obesity	Phase 2	GB	GW Pharmaceuticals Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04201197 (CTgov)	Phase 1	Medication interactions	22	Inje cocktail (Inje Cocktail)	xanwsvudvq(bawrnefavj) = teudkaolcy wjyhimhxhz (adgeuuiwrq, snkyvxgbrp - xvqeklcdpe) View more	-	24 Jul 2023
				Inje cocktail+THC Cannabis extract (Inje Cocktail + THC Extract)	xanwsvudvq(bawrnefavj) = jymqscrlqf wjyhimhxhz (adgeuuiwrq, afmbkvyjde - srramigdam) View more
Pubmed \| CNS Neurosci Ther	Phase 3	Muscle Spasticity	-	THC/CBD oromucosal spray	eobfddppvd(sfsnxamcrv) = jibtwkolxs uaeauqugpl (tjeavtsdln )	-	01 Mar 2015
NCT01491490 (GWMD09126, CTgov)	Phase 2	Dyslipidemias \| Schizophrenia \| Weight Gain \| Psychotic Disorders	2	GWP42003 : GWP42004 (40:1) (GWP42003 : GWP42004 (40:1))	jbdpcyygvs(acymrdhtsc) = ggfliaitvo yvincslyrw (woyatyhyfn, zjketcnvmd - bpthkljfei) View more	-	01 Nov 2013
				Placebo (Placebo)	jbdpcyygvs(acymrdhtsc) = nxqciqkbft yvincslyrw (woyatyhyfn, mmugfsdofo - nmlhqqzxaj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis